Seasonal timing of anti–PD-1 therapy and survival outcomes in a real-world pan-cancer coho

430 patients with metastatic solid tumors treated with anti-PD-1 monotherapy between 2015 and 2024 were analyzed for seasonal effects on survival. Summer initiation of therapy was associated with significantly longer median progression-free survival (6.2 vs. 3.6 months) and overall survival (21.5 vs. 12.4 months) compared to winter initiation. This dataset, authored by Haydar C. Yuksel and shared on figshare, provides real-world clinical evidence on circannual variation in immune checkpoint inhibitor efficacy.

Use Cases

• Analyze the association between season of treatment initiation and progression-free survival based on Kaplan-Meier estimates and log-rank tests.
• Model the effect of seasonal timing on overall survival using multivariable Cox regression based on the patient cohort.
• Validate survival advantages using propensity score matching techniques described in the study.
• Perform landmark analysis to assess survival outcomes based on the 3-month landmark method mentioned.
• Investigate seasonal modulation of host immunity as a factor in immunotherapy response based on the study's hypothesis.

Strengths

• Analysis includes 430 patients from a real-world cohort treated between 2015 and 2024.
• Results are supported by multiple statistical methods: Kaplan-Meier estimates, log-rank tests, multivariable Cox regression, and propensity score matching.
• The dataset is openly shared under a CC-BY-4.0 license.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count for the underlying data is unknown, which may limit suitability assessment.
• Data is from a single center, which may limit generalizability.

Provenance

Source

figshare

Collection Method

Retrospective analysis of adults with metastatic solid tumors treated at a single center.

Time Range

2015 to 2024

Freshness

Last updated 2026-06-04 08:25:55; freshness should be verified.